Moody Aldrich Partners LLC Lowers Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Moody Aldrich Partners LLC trimmed its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 8.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,104 shares of the biopharmaceutical company’s stock after selling 7,908 shares during the quarter. Intra-Cellular Therapies makes up about 1.2% of Moody Aldrich Partners LLC’s portfolio, making the stock its 26th biggest holding. Moody Aldrich Partners LLC’s holdings in Intra-Cellular Therapies were worth $6,666,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Perceptive Advisors LLC raised its position in shares of Intra-Cellular Therapies by 62.6% in the second quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company’s stock worth $117,557,000 after acquiring an additional 661,052 shares during the period. Millennium Management LLC boosted its position in Intra-Cellular Therapies by 214.5% during the second quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company’s stock worth $60,895,000 after purchasing an additional 606,358 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in Intra-Cellular Therapies by 21.2% in the second quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $205,470,000 after purchasing an additional 525,000 shares during the period. Marshall Wace LLP purchased a new stake in shares of Intra-Cellular Therapies in the second quarter valued at approximately $34,178,000. Finally, Hood River Capital Management LLC acquired a new position in shares of Intra-Cellular Therapies during the 2nd quarter worth approximately $33,390,000. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock traded up $1.00 during trading on Thursday, hitting $76.02. 25,406 shares of the stock traded hands, compared to its average volume of 865,406. The firm has a market capitalization of $8.03 billion, a P/E ratio of -64.67 and a beta of 1.00. Intra-Cellular Therapies, Inc. has a 52-week low of $45.50 and a 52-week high of $84.89. The firm’s fifty day moving average price is $74.49 and its 200-day moving average price is $72.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.03. The business had revenue of $161.40 million for the quarter, compared to analyst estimates of $157.74 million. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The company’s quarterly revenue was up 45.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.45) EPS. As a group, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.59 earnings per share for the current year.

Insider Transactions at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 53,013 shares of Intra-Cellular Therapies stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total value of $4,010,433.45. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $80,970,388.85. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Sharon Mates sold 53,013 shares of the business’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total value of $4,010,433.45. Following the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $80,970,388.85. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mark Neumann sold 18,714 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $75.08, for a total value of $1,405,047.12. Following the transaction, the executive vice president now directly owns 29,700 shares in the company, valued at approximately $2,229,876. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 175,316 shares of company stock worth $13,037,345. 3.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of Intra-Cellular Therapies from $79.00 to $81.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st. Piper Sandler raised shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and raised their price target for the company from $68.00 to $92.00 in a research note on Friday, September 6th. The Goldman Sachs Group cut their price objective on Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. UBS Group lowered their price target on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Finally, Morgan Stanley increased their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, Intra-Cellular Therapies has an average rating of “Moderate Buy” and a consensus target price of $96.62.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.